Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
AIs appear more effective as adjuvant therapy, more trials needed
October 20th, 2005
Aromatase inhibitors appear more effective than tamoxifen at preventing breast cancer, however, more trials are needed to answer important questions regarding treatments. "Endocrine therapy of hormone receptor-positive breast tumors is widely used as palliative therapy for metastatic breast cancer and as adjuvant therapy for early stage breast cancer," according to researchers from the United States. "Tamoxifen has been the definitive standard of hormonal therapies for the last 30 years because of its documented efficacy and reasonable safety profile." R. Kudchadkar and colleagues stated, "Based on encouraging results from trials utilizing the...
Source: Women's Health Weekly (2005-10-20)
|
